Vyondys 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in Package Insert - ELEVIDYS (fda.gov). Revised 10/2024. Member
by UMP Subcommittee 2024Elevidys in accordance to the package insert for Elevidys (See Appendix A for Vyondys 53 intravenous infusion [prescribing information].
Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics, Inc.; March 2024. 2. Clinical Pharmacology [database online]. Tampa, FL
Viltepso [package insert], Paramus, NJ: NS Pharma, Inc.; March 2024. Vyondys 53 [package insert], Cambridge, MA: Sarepta Therapeutics
(Vyondys 53), viltolarsen (Viltepso)), or Casimersen (Amondys 45) are Per the Amondys 45 package insert, Amondys 45 was approved by the FDA under
Vyondys 53 while maintaining optimal therapeutic outcomes. References. 1. Vyondys 53 [package insert]. Cambridge, MA: Sarepta Therapeutics
Amondys 45, Exondys 51. Vyondys 53, Viltepso) after Elevidys PACKAGE INSERT INFORMATION: INDICATION, AGE, DOSE, AND ANY. PRE
Vyondys 53; new prior authorization for Vyondys 53. Coding Reviewed Package inserts. U.S. National Library of Medicine, National
Vyondys 53 [package insert]. Cambridge, MA. Sarepta Therapeutics, Inc. December 2024. 3. Viltepso [package insert]. Paramus, NJ; NS Pharma; August 2024
I would like to know more about this package. ^.^